Estimating the returns to UK publicly funded cancer-related research in terms of the net value of improved health outcomes.
Estimating the returns to UK publicly funded cancer-related research in terms of the net value of improved health outcomes.
复制标题
根据改善健康成果的净价值，估计对英国公开资助的与癌症相关的研究的回报。
DOI：
10.1186/1741-7015-12-99
复制
发表时间：
2014-06-16
期刊：
影响因子：
9.3
通讯作者：
Grant J
中科院分区：
文献类型：
--
作者：
Glover M;Buxton M;Guthrie S;Hanney S;Pollitt A;Grant J
基于一种评估心血管研究的经济回报的方法，我们估计了英国公共和慈善机构资助的癌症相关研究的经济回报，这些研究产生于改善的健康结果的净值。为了评估英国癌症相关研究的这些经济回报，我们估计：1)1970年至2009年英国癌症相关研究的公共和慈善支出；2)净货币效益(NMB)，即以货币形式(使用GB 25000 GB的QALY的基本价值)衡量的健康效益(QALY)减去提供该效益的成本，从1991年到2010年的优先干预清单；3)可归因于英国研究的NMB比例；4)研究资金和健康收益之间的时间间隔；5)与癌症相关的健康效益研究投资的内部收益率。我们使用敏感性分析来分析内部收益率估计中的不确定性，以说明一些关键参数的影响。按2011/12年度价格计算，1970年至2009年用于癌症相关研究的总支出为150亿GB。1991年至2010年，从优先干预措施中获得的590万个QALYs中，NMB为1240亿GB。在计算内部回报率时，估计所用的时间为15年。我们将估计可归因于英国研究的年度NMB的17%(1991年至2010年的20个十年中的每一年)与15年前的20个亿年(即1976至1995年)的研究投资联系起来。这产生了10%的最佳估计IRR，而之前心血管疾病研究的估计IRR为9%。敏感性分析证明了减少吸烟作为改善癌症相关健康结果的主要来源的重要性。我们已经展示了从健康净收益到英国癌症相关研究的公共和慈善资金的实质性IRR，并进一步验证了我们最初在评估心血管研究回报时使用的方法。在这样做的过程中，我们强调了需要在进一步调查中加强的一些弱点和关键假设。然而，这些谨慎的估计表明，过去癌症研究的回报是可观的，并证明了1976年至1995年期间所做的投资是合理的。
Building on an approach developed to assess the economic returns to cardiovascular research, we estimated the economic returns from UK public and charitable funded cancer-related research that arise from the net value of the improved health outcomes. To assess these economic returns from cancer-related research in the UK we estimated: 1) public and charitable expenditure on cancer-related research in the UK from 1970 to 2009; 2) net monetary benefit (NMB), that is, the health benefit measured in quality adjusted life years (QALYs) valued in monetary terms (using a base-case value of a QALY of GB£25,000) minus the cost of delivering that benefit, for a prioritised list of interventions from 1991 to 2010; 3) the proportion of NMB attributable to UK research; 4) the elapsed time between research funding and health gain; and 5) the internal rate of return (IRR) from cancer-related research investments on health benefits. We analysed the uncertainties in the IRR estimate using sensitivity analyses to illustrate the effect of some key parameters. In 2011/12 prices, total expenditure on cancer-related research from 1970 to 2009 was £15 billion. The NMB of the 5.9 million QALYs gained from the prioritised interventions from 1991 to 2010 was £124 billion. Calculation of the IRR incorporated an estimated elapsed time of 15 years. We related 17% of the annual NMB estimated to be attributable to UK research (for each of the 20 years 1991 to 2010) to 20 years of research investment 15 years earlier (that is, for 1976 to 1995). This produced a best-estimate IRR of 10%, compared with 9% previously estimated for cardiovascular disease research. The sensitivity analysis demonstrated the importance of smoking reduction as a major source of improved cancer-related health outcomes. We have demonstrated a substantive IRR from net health gain to public and charitable funding of cancer-related research in the UK, and further validated the approach that we originally used in assessing the returns from cardiovascular research. In doing so, we have highlighted a number of weaknesses and key assumptions that need strengthening in further investigations. Nevertheless, these cautious estimates demonstrate that the returns from past cancer research have been substantial, and justify the investments made during the period 1976 to 1995.
登录
查看更多内容
影响因子：
5.4
作者：
Hanney, S;Mugford, M;Buxton, M
通讯作者：
Buxton, M
影响因子：
5.4
作者：
DRUMMOND, MF;DAVIES, LM;FERRIS, FL
通讯作者：
FERRIS, FL
影响因子：
6.4
作者：
Bjerregaard, Bine Kjoller;Raaschou-Nielsen, Ole;Riboli, Elio
通讯作者：
Riboli, Elio
影响因子：
168.9
作者：
Johnston, SC;Rootenberg, JD;Elkins, JS
通讯作者：
Elkins, JS
影响因子：
105.7
作者：
Grant, J;Cottrell, R;Fawcett, G
通讯作者：
Fawcett, G